Shared on01 Aug 25Fair value Increased 7.69%
The upward revision in the fair value price target for Oncology Institute reflects modest improvements in both revenue growth and net profit margin forecasts, with the consensus analyst price target rising from $6.50 to $7.00. What's in the News The Oncology Institute announced it will be the exclusive oncology provider for over 80,000 Medicaid patients under the Silver Summit Health plan in Nevada, expanding access via three locations.